Cleared First Four Monotherapy Doses and Initial Combination Cohort with No Dose Limiting Toxicities at any Dose Level KVA12123 Monotherapy…
Second study of Allocetra in knee osteoarthritis, following the on-going Phase I/II trial in pre-surgery, end-stage osteoarthritis, that is continuing…
BRISBANE, Calif., Jan. 17, 2024 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a clinical-stage…
BASKING RIDGE, N.J., Jan. 17, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage…
BOSTON, Jan. 17, 2024 (GLOBE NEWSWIRE) -- Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells…
Up to 40% of women with triple negative breast cancer (TNBC) experience metastasis to their brain, which affects physical function,…
Awards Mr. Freedberg an Inducement Grant in accordance with Nasdaq Listing Rule 5635(c)(4)NEW HAVEN, Conn., Jan. 16, 2024 (GLOBE NEWSWIRE)…
- Data from first tranche of MSS CRC patients treated with ADG126 10 mg/kg every three weeks (Q3W) in dose…
NEW YORK, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS – NASDAQ: CLLS) (the “Company”), a clinical-stage biotechnology company…
GENEVA, SWITZERLAND / ACCESSWIRE / January 17, 2024 / With cancer projected to escalate to 29 million cases by 2040[1],…